We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oscillating Pulsed Electric Fields Strike Major Blow to Resistant Bacteria and Cancer

By LabMedica International staff writers
Posted on 29 Oct 2013
Print article
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Oscillating pulsed electric field (OPEF) technology is delivering a one-two punch against cancer and antibiotic-resistant bacteria using a pulsed electronic signal that destroys cancer cells and disables antibiotic resistance in deadly methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas bacteria.

Novobiotronics (Saratoga Springs, NY, USA), a world leader in research on the biologic effects of OPEFs as a future nontoxic medical treatment, was the first company to confirm the capability of OPEFs to destroy 30%–60% of leukemia cells. In laboratory research, OPEF also demonstrated an ability to slow cancer growth by up to 60%. OPEF has also shown an ability to disarm antibiotic resistance in the lethal bacteria MRSA, rendering it susceptible to typically available antibiotics as well as inhibiting its growth.

Novobiotronics Inc., a nonprofit educational and scientific research, has report a significant breakthrough in the battle against cancer and harmful antibiotic-resistant strains of bacteria including the “superbug” deadliness of MRSA, and Pseudomonas aeruginosa (PS).

Anthony Holland, president of Novobiotronics, reported the findings of recent laboratory research done in collaboration with the State University of New York (Stony Brook, USA) that their new electronic treatment of antibiotic resistant MRSA and PS has both a bacteriostatic effect as well as a bactericidal effect when used in combination with tiny amounts of conventional antibiotics to which the deadly organisms are otherwise normally resistant.

The current standard medical treatment of antibiotic-resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Physicians even induce some patients into a coma to reduce the severity of the drug side effects.

Novobiotronics’ new technology involves the use of a “plasma antenna,” a type of a helium gas filled fluorescent light used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These OPEFs can kill cancer cells, slow the growth rate of the cancer cells and bacteria greatly, and actually quash the bacteria’s ability to resist antibiotics. When used in combination with very small amounts of a traditional antibiotic, OPEF has demonstrated an ability to destroy MRSA and PS bacteria.

Novobiotronics’ collaborators from the State University of New York presented their joint findings at a September 2013 meeting of the American Society for Microbiology, held in Denver (CO, USA).

Related Links:

Novobiotronics
State University of New York


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.